Diabetes News

FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes (AstraZeneca and Bristol-Myers Squibb)

An FDA advisory committee voted 8-4 Thursday in favor of approval of a new ultra-long-acting insulin for type 1 and type 2 diabetes. (medpage TODAY)

This evidence summary considers the use of insulin degludec in adults with type 2 diabetes (NICE)

This evidence summary considers the use of insulin degludec in adults with type 1 diabetes (NICE)

The medication used in the study has the generic name nabilone, and is currently used in Canada to treat nausea in chemotherapy patients. This study gives doctors more evidence to support its prescription for treating neuropathy pain in diabetics (University of Calgary, Hotchkiss Brain Institute)

A randomized controlled trial suggests that metformin should be considered for treatment of overt diabetes and early a2 gestational diabetes in pregnancy (American Journal of Perinatology)

Metformin is a potent inducer of hepatic FGF21 expression and that the effect of metformin seems to be mediated through AMPK activation (Experimental Diabetes Research)

This study is the first to show that a DPP-4 inhibitor, sitagliptin, reduces inflammatory cytokines and improves the unfavorable M1/M2-like phenotypes of peripheral blood monocytes in Japanese type 2 diabetic patients (Metabolism – Clinical and Experimental)

In addition, the FDA has ruled that no further clinical investigation is necessary to demonstrate the safety and effectiveness of this proposed product (Boston Therapeutics)

The study results showed that in addition to clinical results showing a statistically significant 48 percent baseline adjusted reduction in nocturnal hypoglycaemia compared with insulin glargine patients treated with LY2605541* reported a statistically significant reduction in the anxiety and fear associated with experiencing a hypoglycaemic event based upon the Adult Low Blood Sugar Survey (Lilly)

The new analyses show linagliptin, alone or in combination with other diabetes therapies, lowered hemoglobin A1c (HbA1c or A1C) in elderly patients with type 2 diabetes, as well as in adults with type 2 diabetes with diabetic nephropathy (renal disease).Data from a fourth study found adding linagliptin to a stable dose of basal insulin improved blood glucose control over 52 weeks without an additional risk of hypoglycemia or weight gain compared to placebo (Lilly)

This review provides an overview of the development of incretin-based therapies and explains their differing modes of action compared with traditional interventions (Clinical Endocrinology)

Novartis announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions for new indications for the use of Galvus® (vildagliptin) and Eucreas® (vildagliptin and metformin) in combination with other treatments for type 2 diabetes patients (Novartis)

A cohort study from the Swedish National Diabetes Register (BMJ)

In patients with Type 2 diabetes, well controlled with metformin monotherapy, addition of liraglutide improves several cardiovascular risk markers beyond glycaemic control (Diabetic Medicine)

New data for Lucentis® (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections. It is estimated that over 80% of visual impairment is preventable when due to conditions such as … diabetic macular edema (DME)

Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs – which account for up to 20 percent of the drugs prescribed to diabetics in the United States — are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes (University of Pennsylvania)

An injection administered once a month by a health care professional, Lucentis is intended to be used along with good diabetic blood sugar control (FDA)

Glycemic control, weight, and treatment satisfaction improved after switching from sitagliptin to liraglutide, albeit with a transient increase in gastrointestinal reactions (Diabetes Care)

The results from both studies confirm that imeglimin displays a superior benefit : risk profile compared with metformin in type 2 diabetes patients. The encouraging tolerability profile of imeglimin could make it suitable for combination with other classes of antidiabetic agents and may increase availability to a wider patient population (Diabetes, Obesity and Metabolism)